Hormonbehandling mot postmenopausal osteoporose – gjeldende anbefalinger bør revideres
Hovedbudskap
Hormonbehandling (østrogen eller østrogen/gestagen) av postmenopausale kvinner øker beintetthet og reduserer faren for fraktur
Hormonbehandling med østrogen og gestagen medfører økt risiko for koronar og cerebrovaskulær sykdom, tromboembolisk sykdom, galleveislidelser og brystkreft
Hormonbehandling har vært førstevalg ved forebyggende behandling mot osteoporose. Retningslinjene for hormonbehandling må revurderes
- 1.
Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endo Rev 2002; 23: 279 – 302.
- 2.
Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis. Comparison of study designs and outcomes in large clinical trials with fracture as an outcome. Endo Rev 2002; 23: 16 – 37.
- 3.
Terapianbefalinger: Behandling av osteoporose. Publikasjon 2001: 05. Oslo: Statens legemiddelverk, 2001.
- 4.
Osteoporose. Veileder for forebygging og behandling. Oslo: Statens Helseundersøkelser, 2001.
- 5.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605 – 13.
- 6.
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49 – 57.
- 7.
Hulley S, Furberg C, Barret-Connor E, Cauly J, Grady D, Haskell W et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58 – 66.
- 8.
Writing group for the Women‘s Health Initiative investigators. Risk and benefits from the Women’s Health Initiative randomised controlled trial. JAMA 2002; 288: 321 – 33.
- 9.
Høibraaten E. Hormonbehandling i overgangsalder og hjerte- og karsykdom Tidsskr Nor Lægeforen 2002; 122: 1564 – 5.
- 10.
Os I, Tonstad S. Hormonbehandling i overgangsalder og hjerte- og karsykdommer – nok en gang Tidsskr Nor Lægeforen 2002; 122: 1808 – 10.
- 11.
Statens legemiddelverk. Nytt om legemidler 2002; 25: 3 – 4.
- 12.
Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis. Lancet 1980; 2: 1151 – 4.
- 13.
Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowics MA, Lane AW et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1 – 9.
- 14.
Mosekilde L, Beck-Nielsen H, Sørensen OH, Nielsen SP, Charles P, Vestergaard P et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women – results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181 – 93.
- 15.
Komulainen MH, Kröger H, Tuppurainen MT, Heikkinen A-M, Alhava E, Honkanen R et al. HRT and vitamin D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomised trial. Maturitas 1998; 31: 45 – 54.
- 16.
Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures. JAMA 2001; 285: 2891 – 7.
- 17.
Grady D, Cummings SR. Postmenopausal hormone therapy for prevention of fractures. How good is the evidence? JAMA 2001; 285: 2909 – 10.
- 18.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002; 288: 872 – 81.
- 19.
Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N et al. Meta-analyses of therapies for postmenopausal osteo V. Meta-analysis of the efficacy of hormone replace therapy in treating and preventing osteoporosis in menopausal women. Endo Rev 2002; 23: 529 – 39.
- 20.
Stevenson JC, Whitehead MI. Hormone replacement therapy. BMJ 2002; 324: 113 – 4.
- 21.
Schrader J, Lüders S. Preventing stroke. BMJ 2002; 323: 687 – 8.
- 22.
Grady D, Brown JS, Vittinghoff E, ApplegateW, Varner S, Snyder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol 2001; 97: 116 – 20.
- 23.
Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA 2002; 287: 591 – 7.
- 24.
Voss S, Quail D, Dawson A, Bäckström T, Aguas F, Erenus M et al. A randomised, double-blind trial comparing raloxifene HCL and continous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002; 109: 874 – 85.
- 25.
Lindsay R. The lack of effect of progestogen on bone. J Reprod Med 1999; 44: 215 – 20.